[⁶⁸Ga]Ga-HKG301(FAP-2286) PET/CT in pancreatic and breast malignancies
Key facts
- Where
- Salzburg, AusztriaSee the site
- Phase
- 2. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you pregnant or breastfeeding?
Where in Ausztria
- Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbHSalzburg, AusztriaToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH
- Trial code
- EU 2026-526498-40-00
- Record updated
- 2026. november 1.
- Original description
To assess diagnostic performance of HKG301 PET/CT in patients with Pancreatic adenocarcinoma (PDAC) and to assess diagnostic performance of HKG301 PET/CT in patients with lobular breast cancer.Read full original descriptionShow less
Diagnostic Performance of [⁶⁸Ga]Ga-HKG301 (FAP-2286) PET/CT in Biologic Borderline Resectable Pancreatic and Invasive Lobular Breast Cancers – FAPTRACE Trial
To assess diagnostic performance of HKG301 PET/CT in patients with Pancreatic adenocarcinoma (PDAC) and to assess diagnostic performance of HKG301 PET/CT in patients with lobular breast cancer.
Inclusion: Adults (≥18 years) with suspicion of and/or histopathology-proven PDAC with primarily resectable tumor and serum CA19-9 levels > 500 U/mL and/or inconclusive findings on conventional imaging; Female adults (≥18 years) with histopathology-proven invasive lobular breast cancer patients with unfavorable receptor status (any stage with HER2-positive or ER < 10%) or with clinical stage II (≥ cT2) or stage III disease; Patients who have undergone or are scheduled for standard initial staging with ceCT, MRI, and [¹⁸F]FDG PET/CT; Patients who gave free written consent to participate in the clinical trial through the Informed Consent Form; Patients willing to comply with all clinical trial procedures and show availability for the duration of the clinical trial; Patients with an ECOG performance status ≤ 2.
Exclusion: Medical or psychiatric conditions that compromise the patient’s ability to give informed consent; Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the clinical trial protocol and follow-up schedule; Known hypersensitivity to radiotracers, or compounds of HKG301; Significantly impaired renal function (creatinine clearance < 60 mL/min according to CKD-EPI); Pregnancy or breastfeeding; Inability to undergo PET/CT scanning (e.g., severe claustrophobia, weight limits or inability to tolerate lying for the duration of a PET/CT scan).